Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Death of Drugs: Understanding the Drivers of Drug Discontinuation in Canada

EF 2025-26

Résumé
Between 2017 and 2023, over 1,000 drugs were permanently discontinued in Canada, often for reasons unrelated to safety or regulation. Such withdrawals can disrupt patient care, requiring therapy substitutions that may lead to adverse outcomes. Commercial withdrawals—due to low profit margins, small market size, and regulatory constraints—represent a market failure where financial incentives are misaligned with public health needs. Older drugs, especially single-source generics, often lose market share once newer alternatives become standard of care, even if therapeutically important. Research quantifying patterns and drivers of permanent drug discontinuation in Canada is limited. This study examines the lifecycle of drugs marketed from 2013 to 2025, using product-level discontinuation, pricing, and volume data to identify factors associated with drug discontinuations. We will analyze sales trends to detect gradual declines, abrupt drops, or seasonal fluctuations and use panel logistic regression to assess economic, regulatory, and therapeutic predictors, including manufacturer type, drug class, formulation, revenue, and clinical demand. This research will clarify the factors driving permanent drug discontinuations and inform policy interventions to ensure reliable patient access.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
572992
Name
Sidhu Gurher K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Death of Drugs: Understanding the Drivers of Drug Discontinuation in Canada
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Drug Access; Drug Discontinuation; Drug Policy; Drug Shortage; Drug Utilization; Health Services Research; Pharmacoeconomics; Pharmacoepidemiology
Abstract
Between 2017 and 2023, over 1,000 drugs were permanently discontinued in Canada, often for reasons unrelated to safety or regulation. Such withdrawals can disrupt patient care, requiring therapy substitutions that may lead to adverse outcomes. Commercial withdrawals—due to low profit margins, small market size, and regulatory constraints—represent a market failure where financial incentives are misaligned with public health needs. Older drugs, especially single-source generics, often lose market share once newer alternatives become standard of care, even if therapeutically important. Research quantifying patterns and drivers of permanent drug discontinuation in Canada is limited. This study examines the lifecycle of drugs marketed from 2013 to 2025, using product-level discontinuation, pricing, and volume data to identify factors associated with drug discontinuations. We will analyze sales trends to detect gradual declines, abrupt drops, or seasonal fluctuations and use panel logistic regression to assess economic, regulatory, and therapeutic predictors, including manufacturer type, drug class, formulation, revenue, and clinical demand. This research will clarify the factors driving permanent drug discontinuations and inform policy interventions to ensure reliable patient access.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sidhu, Gurher K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~